Cashu Finance
  • Terminal
  • Stocks
  • Spotlight
  • Research
Log inSign Up
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. TECH

Market Cap: $11.29B

BC

Bio-Techne Corporation

TECH
NASDAQUSD
Purchase TECH
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutivePatentsEarnings Surprise
Cashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

–
USD
–(–)

Open

$70.84

Prev. Close

$72.08

High

$70.845

Low

$70.62

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

CEOKim Kelderman
SectorHealthcare
IndustryBiotechnology
Employees3K
IPO DateFeb 9, 1989
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address614 McKinley Place N.E.
City / State / ZIPMinneapolis, MN, 55413
CountryUnited States
Phone612 379 8854
Websitehttps://www.bio-techne.com

Recently from Cashu